Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Cash Flow Quality Index
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Cash Flow Quality Index of 0.98x as of June 2023. Operating cash flow of $40.67 Million is below net income of $41.56 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore CTNM total asset value for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Quality Index (2023–2023)
Historical Cash Flow Quality Index for Contineum Therapeutics, Inc. Class A Common Stock across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Contineum Therapeutics, Inc. Class A Com tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Year-by-year earnings quality comparison for Contineum Therapeutics, Inc. Class A Common Stock. For live market cap and the full company financial profile, see CTNM market cap.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.85x | $19.35 Million | $22.72 Million | — |